Research review · Sources checked October 15, 2026

Published February 14, 2026 · Updated October 30, 2026

Epitalon: what the research shows

Epitalon (also written Epithalon) is the tetrapeptide Ala-Glu-Asp-Gly, designed from the composition of a bovine pineal extract. It is not an FDA-approved drug, and its evidence base is mainly in vitro and animal work.[1][2]

Where the research comes from

Epitalon was designed by V. Kh. Khavinson’s group at the Saint Petersburg Institute of Bioregulation and Gerontology, which reports lifespan extension in mice and fruit flies and restored melatonin and cortisol rhythms in old rhesus monkeys.[3] These are animal findings from the developing group. A 2025 review summarizes 25 years of in vitro, in vivo, and in silico studies reporting antioxidant, neuroprotective, and melatonin-related effects, and notes that its mechanisms remain uncertain and that physico-chemical and structural studies are limited.[1]

The telomere claim

The most-repeated claim is that epitalon lengthens telomeres. A 2025 cell-culture study found dose-dependent telomere extension in normal human epithelial and fibroblast cells through hTERT and telomerase upregulation. It also found telomere extension in breast cancer cell lines through the ALT pathway.[4] This is cell-line evidence; it does not show effects on aging, disease, or lifespan in people.

Regulatory status

No FDA-approved drug product contains epitalon; a Drugs@FDA search returns no approved application.[2] FDA lists epitalon among substances previously placed in compounding category 2 whose nominations were withdrawn. FDA “has not identified safety-related information regarding epitalon for the proposed route” and flags aggregation and impurity risk.[5]

Update, October 28, 2026: HHS made public a draft enforcement-discretion policy that lists epitalon among six peptides (the others are BPC-157, KPV, MOTS-c, semax and TB-500). HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound these peptides under 10 conditions.[6] For epitalon, Appendix B names epitalon acetate, only in subcutaneous or intramuscular injectable forms “dispensed in intermittent courses.”[6] The conditions include bulk powder from an FDA-registered facility with a certificate of analysis, one listed active ingredient per product, reporting of serious adverse events and a patient-specific prescription.[6] HHS calls the document a draft, open to comment on regulations.gov (Docket No. HHS-OASH-2026-0496) until 2 weeks after its October 30, 2026 Federal Register publication (November 13, 2026, per regulations.gov), and says it is not binding and may be revisited if a safety signal or quality problem arises.[6] This is not an FDA approval: compounded drugs are not reviewed by FDA for safety or effectiveness, and the policy records that FDA’s drug center recommended against listing epitalon.[6] For what it does and doesn’t change, see our FDA peptide policy explainer. This summary is not legal advice.

What is not known

There are no independent randomized trials with clinical outcomes, no established human dose, and no long-term safety data.[1][5]

This page summarizes published research and regulatory documents. It is not medical advice and does not recommend using, sourcing, or dosing any of these substances.